Prevalence of thrombophilia in women with severe ovarian hyperstimulation syndrome and cost-effectiveness of screening

Fertility and Sterility

Volumn 81, Issue 4, 2004, Pages 989-995

  Fábregues, Francisco ^b   Tàssies, Dolors ^b   Reverter, Juan C ^b   Carmona, Francisco ^b   Ordinas, Antonio ^b   Balasch, Juan ^a,b  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Factor V Leiden; IVF; Ovarian hyperstimulation syndrome; Prothrombin mutation; Thrombophilia

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 5 LEIDEN; CARDIOLIPIN ANTIBODY; LUPUS ANTICOAGULANT; PROTEIN C; PROTEIN S; PROTHROMBIN COMPLEX;

ANALYTIC METHOD; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE MARKER; FEMALE; FERTILIZATION IN VITRO; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; OVARY DISEASE; PREVALENCE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; SCREENING TEST; THROMBOPHILIA; THROMBOSIS; UNIVERSITY HOSPITAL;

ADULT; ALANINE; CASE-CONTROL STUDIES; COST-BENEFIT ANALYSIS; FACTOR V; FEMALE; GENETIC SCREENING; GLYCINE; HUMANS; MALE; MUTATION; OVARIAN HYPERSTIMULATION SYNDROME; POINT MUTATION; PREVALENCE; PROTHROMBIN; SEVERITY OF ILLNESS INDEX; THROMBOPHILIA;

EID: 17444449201     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2003.09.042     Document Type: Article

References (52)

1. Pride S.M., James C.S.J., Yuen B.H. The ovarian hyperstimulation syndrome. Semin Reprod Endocrinol. 8:1990;247-260.
2. Delvigne A., Demoulin A., Smitz J., Donnez J., Koninckx P., Dhont M., et al. The ovarian hyperstimulation syndrome in in-vitro fertilization a Belgian multicenter study. Hum Reprod. 8:1993;1353-1360.
3. Elchalal U., Schenker J.G. The pathophysiology of ovarian hyperstimulation syndrome - views and ideas. Hum Reprod. 12:1997;1129-1137.
4. Balasch J., Fábregues F., Arroyo V. Peripheral arterial vasodilation hypothesis a new insight into the pathogenesis of ovarian hyperstimulation syndrome. Hum Reprod. 13:1998;2718-2730.
5. Schenker J.G., Weinstein D. Ovarian hyperstimulation syndrome a current survey. Fertil Steril. 30:1978;255-268.
6. Phillips L.L., Gladstone W., van de Wiele R. Studies of the coagulation and fibrinolytic systems in hyperstimulation syndrome after administration of human gonadotrophins. J Reprod Med. 14:1975;138-143.
7. Inbar O.J., Levran D., Mashiach S., Dor J. Ischemic stroke due to induction of ovulation with clomiphene citrate and menotropins without evidence of ovarian hyperstimulation syndrome. Fertil Steril. 62:1994;1075-1076.
8. Aurousseau M.H., Samama M.M., Belhassen A., Herve F., Hugues J.N. Risk of thromboembolism in relation to an in vitro fertilization programme three case reports. Hum Reprod. 10:1995;94-97.
9. Aboulghar M.A., Mansour R.T., Serour G.I., Amin Y.M. Moderate ovarian hyperstimulation syndrome complicated by deep cerebrovascular thrombosis. Hum Reprod. 13:1998;2088-2091.
10. Loret de Mola J.R., Kiwi R., Austin C., Goldfarb J.M. Subclavian deep vein thrombosis associated with the use of recombinant follicle-stimulating hormone (Gonal-F) complicating mild ovarian hyperstimulation syndrome. Fertil Steril. 73:2000;1253-1255.
11. Lane D.A., Mannuci P., Bauer K.A., Bertina R.M., Bochkov N.P., Boulyjenkov V., et al. Inherited thrombophilia. Part I. Thromb Haemost. 76:1996;651-661.
12. Dulitzky M., Cohen S.B., Inbal A., Seidman D.S., Soriano D., Lidor A., et al. Increased prevalence of thrombophilia among women with severe ovarian hyperstimulation syndrome. Fertil Steril. 77:2002;463-467.
13. Horstkamp B., Lübke M., Kentenich H., Riess H., Buscher U., Lichtenegger W. Internal jugular vein thrombosis caused by resistance to activated protein C as a complication of ovarian hyperstimulation after in-vitro fertilization. Hum Reprod. 11:1996;280-282.
14. Hollemaert S., Wautrecht J.C., Capel P., Abramowicz M.J., Englert Y., Delbaere A. Thrombosis associated with ovarian hyperstimulation syndrome in a carrier of the factor V Leiden mutation. Thromb Haemost. 76:1996;275-277.
15. Ellis M.H., Nun I.B., Rathaus V., Werner M., Shenkman L. Internal jugular vein thrombosis in patients with ovarian hyperstimulation syndrome. Fertil Steril. 69:1998;140-142.
16. Todros T., Carmazzi C.M., Bontempo S., Gaglioti P., Donvito V., Massobrio M. Spontaneous ovarian hyperstimulation syndrome and deep vein thrombosis in pregnancy. Hum Reprod. 14:1999;2245-2248.
17. Bertina R.M. The prothrombin 20210 G to A variation and thrombosis. Curr Opin Hematol. 5:1998;339-342.
18. Marchetti M., Quaglini S., Barosi G. Cost-effectiveness of screening and extended anticoagulation for carriers of both factor V Leiden and prothrombin G20210A. Q J Med. 94:2001;365-372.
19. Golan A., Ron-El R., Herman A., Soffer Y., Weinraub Z., Caspi E. Ovarian hyperstimulation syndrome an update review. Obstet Gynecol Surv. 44:1989;430-440.
20. Balasch J., Fábregues F., Creus M., Moreno V., Puerto B., Peñarrubia J., et al. Pure and highly purified follicle-stimulating hormone alone or in combination with human menopausal gonadotrophin for ovarian stimulation after pituitary suppression in in-vitro fertilization. Hum Reprod. 11:1996;2400-2404.
21. Dahlbäck B., Carlsson M., Svensson P.J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C prediction of a cofactor to activated protein C. Proc Nat Acad Sci U S A. 90:1993;1004-1008.
22. Jorquera J.I., Montoro J.M., Fernández M.A., Aznar J.A., Aznar J. Modified test for activated protein X resistance. Lancet. 344:1994;1162-1163.
23. Boom R., Sol C.J.A., Salimans M.M., Jansen C.L., Wertheim-van Dillen P.M., van der Noordaa J. Rapid and simple method for purification of nucleic acids. J Clin Microbiol. 28:1990;495-503.
24. Thein S.L., Walance R.B. The use of synthetic oligonucleotides as specific hybridization probes in the diagnosis of genetic disorders. Davis K.E. Human genetic diseases, a practical approach. 1986;33-50 IRL Press, Oxford.
25. Muñoz-Rodriguez F.J., Reverter J.C., Font J., Tàssies D., Espinosa G., Cervera R., et al. Clinical significance of acquired activated protein C resistance in patients with systemic lupus erythematosus. Lupus. 11:2002;730-735.
26. Poort S.R., Rosendaal F.R., Reitsma P.H., Berina R.M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 88:1996;3698-3703.
27. Abildgaard U., Lie M., Odegard O.R. Antithrombin (heparin cofactor) assay with new chromogenic substrates (S-2238 and Chromozyme TH). Thromb Res. 11:1977;549-553.
28. Bertina R.M., Broekmans A.W., Krommenhoek-van Es C., van Wijngaarden A. The use of a functional and immunological assay for plasma protein C in the study of the heterogenity of congenital protein C deficiency. Thromb Haemost. 51:1984;1-5.
29. Amiral J., Grosley M., Boyer-Neumann C., Marfaing-Koka A., Peynaud-Debayle E., Wolf M., et al. New direct assay of free protein S antigen using two distinct monoclonal antibodies specific for the free form. Blood Coagul Fibrinolysis. 5:1994;179-186.
30. Brandt J.T., Triplett D.A., Alving B., Scharrer I. Criteria for the diagnosis of lupus anticoagulant an update. Thromb Haemost. 74:1995;1185-1190.
31. Gharavi A.E., Harris E.N., Asherson R.A., Hughes G.R.V. Anticardiolipin antibodies isotype distribution and phospholipid specificity. Ann Rheum Dis. 46:1987;1-6.
32. McColl M.D., Walker I.D., Greer I.A. The role of inherited thrombophilia in venous thromboembolism associated with pregnancy. Br J Obstet Gynaecol. 106:1999;756-766.
33. Rosendaal F.R., Helmerhorst F.M., Vandenbroucke J.P. Oral contraceptives, hormone replacement therapy and thrombosis. Thromb Haemost. 86:2001;112-123.
34. Aillaud M.F., Succo E., Alessi M.C., Gandois J.M., Gallian P., Morange P., et al. Resistance to activated protein C - diagnostic strategy in a laboratory of hemostasis. Thromb Haemost. 74:1995;1197-1207.
35. Altés A., Souto J.C., Mateo J., Borrell M., Fontcuberta J. Activated protein C resistance assay when applied in the general population. Am J Obstet Gynecol. 176:1997;358-359.
36. Creinin M.D., Lisman R., Strickler R.C. Screening for factor V Leiden mutation before prescribing combination oral contraceptives. Fertil Steril. 72:1999;646-651.
37. Aune B., Hoie K.E., Oian P., Holst N., Osterud B. Does ovarian stimulation for in vitro fertilization induce a hypercoagulable state? Hum Reprod. 6:1991;925-927.
38. Biron C., Galtier-Dereure F., Rabesandratana H., Bernard I., Aguilar-Martinez P., Schved J.F., et al. Hemostasis parameters during ovarian stimulation for in vitro fertilization results of a prospective study. Fertil Steril. 67:1997;104-109.
39. Stewart J.A., Hamilton P.J., Murdoch A.P. Thromboembolic disease associated with ovarian stimulation and assisted conception techniques. Hum Reprod. 12:1997;2167-2173.
40. Todorow S., Schricker S.T., Siebzehnruebl R.B., Neidhardt B., Wildt L., Lang N. Von Willebrand factor an endothelial marker to monitor in vitro fertilization patients with ovarian hyperstimulation syndrome. Hum Reprod. 8:1993;2039-2046.
41. Balasch J., Reverter J.C., Fábregues F., Tassies D., Ordinas A., Vanrell J.A. Increased induced monocyte tissue factor expression by plasma from patients with severe ovarian hyperstimulation syndrome. Fertil Steril. 66:1996;608-613.
42. Kodama H., Takeda S., Fukuda J., Miya H., Shimizu Y., Murata M., et al. Activation of plasma kinin system correlates with severe coagulation disorders in patients with ovarian hyperstimulation syndrome. Hum Reprod. 12:1997;891-895.
43. Hellgren M., Svensson P.J., Dahlbäck B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol. 173:1995;210-213.
44. Pasi K.J., Perry D.J., Lee C.A. Thromboembolism and the combined oral contraceptive pill. Lancet. 345:1996;1437.
45. Dahlbäck B. Are we ready for factor V Leiden screening? Lancet. 347:1996;1346-1347.
46. Vandenbroucke J.P., van der Meer F.J.M., Helmerhorst F.M., Rosendaal F.R. Factor V Leiden should we screen oral contraceptive users and pregnant women? Br Med J. 313:1996;1127-1130.
47. McDonough P.G. Estrogen levels and thrombophilia - an intervening variable or a confounder? Fertil Steril. 78:2002;889-890.
48. Bellver J., Simón C., Pellicer A. Estrogen levels and thrombophilia - an intervening variable or a confounder? Fertil Steril. 78:2002;887-888.
49. Seligsohn U., Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med. 344:2001;1222-1231.
50. Mushlin A.I., Ruchlin H.S., Callahan M.A. Cost-effectiveness of diagnostic tests. Lancet. 358:2001;1353-1355.
51. Kaunitz A.M. Oral contraceptive use and venous thromboembolism. Translating epidemiologic data into clinical practice. ACOG Clin Rev. 4:1999;1-12.
52. Clark P., Twaddle S., Walker I.D., Scott L., Greer I.A. Cost-effectiveness of screening for the factor V Leiden mutation in pregnant women. Lancet. 359:2002;1919-1920.